PT  - JOURNAL ARTICLE
AU  - SHINSUKE KAZAMA
AU  - JOJI KITAYAMA
AU  - MASAYA HIYOSHI
AU  - YOSHITAKA TAKETOMI
AU  - MAKOTO MURAKAMI
AU  - TAKESHI NISHIKAWA
AU  - TOSHIAKI TANAKA
AU  - JUNICHIRO TANAKA
AU  - TOMOMICHI KIYOMATSU
AU  - KAZUSHIGE KAWAI
AU  - KEISUKE HATA
AU  - HIRONORI YAMAGUCHI
AU  - HIROAKI NOZAWA
AU  - SOICHIRO ISHIHARA
AU  - EIJI SUNAMI
AU  - TOSHIAKI WATANABE
TI  - Phospholipase A2 Group III and Group X Have Opposing Associations with Prognosis in Colorectal Cancer
DP  - 2015 May 01
TA  - Anticancer Research
PG  - 2983--2990
VI  - 35
IP  - 5
4099  - http://ar.iiarjournals.org/content/35/5/2983.short
4100  - http://ar.iiarjournals.org/content/35/5/2983.full
SO  - Anticancer Res2015 May 01; 35
AB  - Background: Although secretory phospholipase A2 (sPLA2) has been shown to be involved in various biological processes, its specific roles in sub-types of cancer development remain to be elucidated. Materials and Methods: We examined the expression of sPLA2 group III (GIII) in 142 patients with colorectal cancer using immunohistochemistry, and its correlation with clinicopathological features and outcomes. In addition, we examined the co-expression of sPLA2GIII and sPLA2GX using serial tissue sections to clarify the roles of both proteins in colorectal carcinogenesis. Results: In 66 cases, diffuse staining of sPLA2GIII was seen; this was defined as the group with high expression. High expression was associated with a significantly higher rate of lymph node metastasis (p=0.02) and poorer survival (p=0.03) compared with low expression. Patients with low sPLA2GIII and high sPLA2GX expression had a significantly higher survival rate than those with high sPLA2GIII and low sPLA2GX expression (p=0.038). Conclusion: sPLA2GIII expression may be used as a risk factor for lymph node metastasis and a prognostic marker in colorectal cancer. In addition, sPLA2GIII and sPLA2GX may play opposing roles in colorectal carcinogenesis.